JST

Renesas Completes Acquisition of Panthronics

Retrieved on: 
Friday, June 2, 2023

Renesas Electronics Corporation (TSE:6723, “Renesas”), a premier supplier of advanced semiconductor solutions, today announced its successful completion of acquiring Panthronics AG (“Panthronics”), a fabless semiconductor company specializing in high-performance wireless products.

Key Points: 
  • Renesas Electronics Corporation (TSE:6723, “Renesas”), a premier supplier of advanced semiconductor solutions, today announced its successful completion of acquiring Panthronics AG (“Panthronics”), a fabless semiconductor company specializing in high-performance wireless products.
  • Renesas also announced 13 “Winning Combination” solution designs that combine Renesas’ products with Panthronics’ unique Near-Field Communication (NFC) technology, showcasing the continued expansion of Renesas’ portfolio, specifically in the connectivity space.
  • The acquisition provides Renesas with in-house capability to instantly capture growing market opportunities for NFC.
  • To immediately demonstrate the companies’ technological advantages, Renesas announced 13 Winning Combinations integrating Renesas’ embedded processing, power, connectivity, and analog portfolios with Panthronics’ unique NFC technology.

Daiichi Sankyo Showcases Latest Research Towards Creating New Standards of Care for Patients with Cancer with Data at ASCO and EHA

Retrieved on: 
Thursday, May 25, 2023

Data from DESTINY-PanTumor02 will be featured in an ASCO press briefing.

Key Points: 
  • Data from DESTINY-PanTumor02 will be featured in an ASCO press briefing.
  • “Our data at ASCO and EHA represent another step forward in realizing our vision to create new standards of care for patients with cancer.
  • Executives from Daiichi Sankyo will provide an overview of the ASCO research data and address questions.
  • Highlights of data from Daiichi Sankyo’s DXd ADC portfolio at 2023 ASCO include:

AnHorn Medicines Presents Research of Novel Protein Degrader for Topical Use at ISID Meeting 2023

Retrieved on: 
Monday, May 15, 2023

TAIPEI, May 15, 2023 /PRNewswire/ -- AnHorn Medicines, a private biotechnology company focused on developing precision medicines for degrading disease-causing proteins, presented its potential first-in-class protein degrader program, AH-001, at the First International Societies for Investigative Dermatology Meeting (ISID 2023) in Tokyo.

Key Points: 
  • TAIPEI, May 15, 2023 /PRNewswire/ -- AnHorn Medicines, a private biotechnology company focused on developing precision medicines for degrading disease-causing proteins, presented its potential first-in-class protein degrader program, AH-001, at the First International Societies for Investigative Dermatology Meeting (ISID 2023) in Tokyo.
  • AnHorn Medicines presented on May 12nd at the First International Societies for Investigative Dermatology Meeting (ISID 2023) as an oral presentation at 3:30 p.m. - 6:00 p.m. JST (UTC+9) (Presentation #1116) during the Concurrent Mini-Symposium 10-Pharmacology and Drug Development.
  • AH-001 is a promising small molecule protein degrader program that effectively reverses dihydrotestosterone (DHT)-induced hair loss in preclinical studies.
  • AnHorn Medicines believes that AH-001 has significant potential as a new treatment for androgenetic alopecia (AGA).

Recruit Holdings Reports Results for the Fourth Quarter and Fiscal Year 2022 Financial Results

Retrieved on: 
Monday, May 15, 2023

Recruit Holdings Co., Ltd. (TSE 6098) today reported the fourth quarter and fiscal year 2022 financial results.

Key Points: 
  • Recruit Holdings Co., Ltd. (TSE 6098) today reported the fourth quarter and fiscal year 2022 financial results.
  • The earnings release and related materials can be accessed on the Recruit Holdings Investor Relations website at https://recruit-holdings.com/en/ir/ .
  • Recruit Holdings will host an earnings call to discuss the results at 4:30 p.m. JST (3:30 a.m. EST) today.
  • The video and transcript of the call will be available on our IR website shortly after the call.

JCB offers discount campaign for JCB cardmembers outside Japan at Tokyo Tower, symbol of Tokyo

Retrieved on: 
Monday, May 15, 2023

To receive this offer, JCB cardmembers simply present the JCB Special Offers campaign page and pay with their JCB Card which was issued outside Japan.

Key Points: 
  • To receive this offer, JCB cardmembers simply present the JCB Special Offers campaign page and pay with their JCB Card which was issued outside Japan.
  • JCB and TOKYO TOWER Co., Ltd. have partnered to welcome tourists from outside of Japan with this special offer to enrich the experience of visiting Japan for JCB cardmembers outside of Japan, and to welcome many visitors to Japan to Tokyo Tower, which has been the symbol of Tokyo and a familiar face since it opened in 1958, as a "uniquely Japanese" experience.
  • As a Japanese brand with a spirit of hospitality, JCB provides services that enrich JCB cardmembers' travel experience.
  • Visit "JCB Global," the official YouTube channel, and the JCB Special Offers website[1] for beneficial campaigns and convenient services in multiple languages.

Nexon Releases Earnings for First Quarter 2023

Retrieved on: 
Thursday, May 11, 2023

NEXON Co., Ltd. (Nexon) (3659.TO), a global leader in Virtual Worlds, today announced the financial results for its first quarter ended on March 31, 2023.

Key Points: 
  • NEXON Co., Ltd. (Nexon) (3659.TO), a global leader in Virtual Worlds, today announced the financial results for its first quarter ended on March 31, 2023.
  • “Our record-breaking first quarter reflects the success of our large and growing portfolio of global franchises,” said Owen Mahoney, President and CEO of Nexon.
  • In Korea, Nexon achieved record-breaking quarterly revenue – up 36% year over year on an as-reported basis.
  • Based on feedback from players, Nexon will follow up with improvements to the user interface and with relentless content updates.

Late-Breaking Turn Biotechnologies Presentation at ISID to Show Cell Reprogramming with ERA™ Technology Renews Skin

Retrieved on: 
Wednesday, May 10, 2023

MOUNTAIN VIEW, Calif., May 10, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell reprogramming company developing novel mRNA medicines for untreatable, age-related conditions, has been invited to present data showing that its epigenetic reprogramming technology rejuvenates human skin.

Key Points: 
  • MOUNTAIN VIEW, Calif., May 10, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell reprogramming company developing novel mRNA medicines for untreatable, age-related conditions, has been invited to present data showing that its epigenetic reprogramming technology rejuvenates human skin.
  • Turn Bio's late-breaking abstract was accepted for presentation during the prestigious International Societies for Investigative Dermatology (ISID) Meeting, in Tokyo, Japan.
  • Data will show that transient reprogramming with Turn Bio's Epigenetic Reprogramming of Aging (ERA™) technology rejuvenates cells within the extracellular matrix (ECM), resulting in comprehensive changes related to improved skin quality and structure.
  • Turn Bio data will be presented by Dr. Edward Hsia, vice president of Dermatology at Turn Bio.

Debbie's Dream Foundation: Curing Stomach Cancer Joins the 15th Annual International Gastric Cancer Congress in Japan for Patient Advocacy Session

Retrieved on: 
Thursday, May 4, 2023

FORT LAUDERDALE, Fla., May 4, 2023 /PRNewswire/ -- Debbie's Dream Foundation: Curing Stomach Cancer (DDF) is joining forces with the International Gastric Cancer Association for the 15th Annual International Gastric Cancer Congress (IGCC). DDF patient advocates will participate in the Patient Advocacy Session on Saturday, June 17, 2023, from 8 a.m. to 12 p.m. JST, from Yokohama, Japan. The half-day session will be live-cast in North America on Friday, June 16, 2023, at 7 p.m. EST, in Europe on Saturday, June 17, 2023, at 1 a.m., and in the United Kingdom on Saturday, June 17, 2023, at 12 a.m. It will feature various panel discussions and presentations highlighting patient advocacy programs, services, and resources to oncologists and aims to provide accurate information to patients and ensure that their views are reflected in their healthcare decision-making. The entire program will be simultaneously translated into different languages, including English, Japanese, Chinese, and Korean.

Key Points: 
  • FORT LAUDERDALE, Fla., May 4, 2023 /PRNewswire/ -- Debbie's Dream Foundation: Curing Stomach Cancer (DDF) is joining forces with the International Gastric Cancer Association for the 15th Annual International Gastric Cancer Congress (IGCC).
  • DDF patient advocates will participate in the Patient Advocacy Session on Saturday, June 17, 2023, from 8 a.m. to 12 p.m. JST, from Yokohama, Japan.
  • "DDF is proud to partner with the 15th Annual IGCC in Japan to help bring patient advocacy to the forefront," said Andrea Eidelman, Chief Executive Officer of DDF.
  • The IGCC 2023 Advocacy Session is supported in part by DDF, My Gut Feeling of Canada, and KIBOUNOKAI of Japan.

TDK Ventures announces DX Week 2023

Retrieved on: 
Thursday, April 27, 2023

DX Week 2023 is an opportunity for attendees to hear presentations and share insights, best practices, and visions with colleagues and industry partners of how digital technologies will make the earth more productive, inclusive, and sustainable.

Key Points: 
  • DX Week 2023 is an opportunity for attendees to hear presentations and share insights, best practices, and visions with colleagues and industry partners of how digital technologies will make the earth more productive, inclusive, and sustainable.
  • "During DX Week 2023, we'll explore the influence that automation, communication, advanced computing, sophisticated data analysis, and other breakthroughs will bear on manufacturing, computing, entertainment, and sustainability," said Nicolas Sauvage, president of TDK Ventures.
  • DX Week 2023 includes three separate sessions set in the top tech centers in the world, where diverse expert panelists will provide definitive insights into how digital technologies are changing the universe.
  • Partnering with TDK Ventures in presenting DX Week 2023 are co-partners Playground and Accel, and partners Sony, Mitsubishi, Yamaha Motor Ventures, and Evoexus.

TDK Ventures announces DX Week 2023

Retrieved on: 
Thursday, April 27, 2023

DX Week 2023 is an opportunity for attendees to hear presentations and share insights, best practices, and visions with colleagues and industry partners of how digital technologies will make the earth more productive, inclusive, and sustainable.

Key Points: 
  • DX Week 2023 is an opportunity for attendees to hear presentations and share insights, best practices, and visions with colleagues and industry partners of how digital technologies will make the earth more productive, inclusive, and sustainable.
  • "During DX Week 2023, we'll explore the influence that automation, communication, advanced computing, sophisticated data analysis, and other breakthroughs will bear on manufacturing, computing, entertainment, and sustainability," said Nicolas Sauvage, president of TDK Ventures.
  • DX Week 2023 includes three separate sessions set in the top tech centers in the world, where diverse expert panelists will provide definitive insights into how digital technologies are changing the universe.
  • Partnering with TDK Ventures in presenting DX Week 2023 are co-partners Playground and Accel, and partners Sony, Mitsubishi, Yamaha Motor Ventures, and Evoexus.